Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRDN-003 in Thyroid Eye Disease
2024-519417-57-00Phase 3Authorised
- Sponsor
- Viridian Therapeutics
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in Graves Orbitopathy (GO) comparing VRDN-003 with TED SC Placebo (2 arms). Primary endpoint: Treatment-emergent adverse events through Week 24. Planned start Jun 2025; status: authorised.
02
Drugs
elegrobart
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2024-519417-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519417-57-00.